Works by Goldman, Jonathan W.

Results: 27

Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2--IA3 EGFR-Mutated NSCLC: ADAURA2.

Published in:

Clinical Lung Cancer, 2023, v. 24, n. 4, p. 376, doi. 10.1016/j.cllc.2023.02.002

By:

Yasuhiro Tsutani;
Goldman, Jonathan W.;
Dacic, Sanja;
Yasushi Yatabe;
Majem, Margarita;
Xiangning Huang;
Chen, Allen;
Toon van der Gronde;
Jie He

Publication type:

Article

A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib.

Published in:

Clinical Lung Cancer, 2022, v. 23, n. 4, p. 300, doi. 10.1016/j.cllc.2022.03.003

By:

Camidge, D. Ross;
Moran, Teresa;
Demedts, Ingel;
Grosch, Heidrun;
Mileham, Kathryn;
Molina, Julian;
Juan-Vidal, Oscar;
Bepler, Gerold;
Goldman, Jonathan W.;
Keunchil Park;
Wallin, Johan;
Wijayawardana, Sameera R.;
Xuejing Aimee Wang;
Wacheck, Volker;
Smit, Egbert

Publication type:

Article

Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer.

Published in:

Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1178313

By:

Goldman, Jonathan W.;
Sholl, Lynette M.;
Dacic, Sanja;
Fishbein, Michael C.;
Murciano-Goroff, Yonina R.;
Rajaram, Ravi;
Szymczak, Sylwia;
Szpurka, Anna M.;
Chao, Bo H.;
Drilon, Alexander

Publication type:

Article

Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management.

Published in:

Therapeutic Advances in Medical Oncology, 2018, v. 10, n. 1, p. 1, doi. 10.1177/1758834017751634

By:

Shen, John;
Chang, Jason;
Mendenhall, Melody;
Cherry, Grace;
Goldman, Jonathan W.;
Kulkarni, Rajan P.

Publication type:

Article

Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study.

Published in:

Molecular Cancer, 2024, v. 23, p. 1, doi. 10.1186/s12943-024-02014-x

By:

Xie, Mingchao;
Vuko, Miljenka;
Rodriguez-Canales, Jaime;
Zimmermann, Johannes;
Schick, Markus;
O'Brien, Cathy;
Paz-Ares, Luis;
Goldman, Jonathan W.;
Garassino, Marina Chiara;
Gay, Carl M.;
Heymach, John V.;
Jiang, Haiyi;
Barrett, J. Carl;
Stewart, Ross A.;
Lai, Zhongwu;
Byers, Lauren A.;
Rudin, Charles M.;
Shrestha, Yashaswi

Publication type:

Article

Current Trial Report: A Multicenter Phase I/Ib study of Capmatinib Plus Trametinib in Patients With Metastatic Nonsmall Cell Lung Center Harboring MET Exon 14 Skipping Mutations and Other MET-Alterations.

Published in:

Clinical Lung Cancer, 2024, v. 25, n. 8, p. 732, doi. 10.1016/j.cllc.2024.07.002

By:

Lara, Matthew S.;
Riess, Jonathan W.;
Goldman, Jonathan W.;
Jiang, Fei;
Bivona, Trever G.;
Blakely, Collin M.

Publication type:

Article

Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD).

Published in:

Clinical Lung Cancer, 2021, v. 22, n. 6, p. 601, doi. 10.1016/j.cllc.2021.06.006

By:

Yu, Helena A.;
Goldberg, Sarah B.;
Le, Xiuning;
Piotrowska, Zofia;
Goldman, Jonathan W.;
De Langen, Adrianus J.;
Okamoto, Isamu;
Cho, Byoung Chul;
Smith, Paul;
Mensi, Ilhem;
Ambrose, Helen;
Kraljevic, Silvija;
Maidment, Julie;
Chmielecki, Juliann;
Li-Sucholeiki, Xiaocheng;
Doughton, Gail;
Patel, Gargi;
Jewsbury, Phil;
Szekeres, Phil;
Riess, Jonathan W.

Publication type:

Article

Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC).

Published in:

2018

By:

Gaut, Daria;
Myung Shin Sim;
Yuguang Yue;
Wolf, Brian R.;
Abarca, Phillip A.;
Carroll, James M.;
Goldman, Jonathan W.;
Garon, Edward B.;
Sim, Myung Shin;
Yue, Yuguang

Publication type:

journal article

Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy.

Published in:

2016

By:

Goldman, Jonathan W.;
Shi, Peipei;
Reck, Martin;
Paz-Ares, Luis;
Koustenis, Andrew;
Hurt, Karla C.

Publication type:

journal article

Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small‐Cell Lung Cancer.

Published in:

CTS: Clinical & Translational Science, 2021, v. 14, n. 2, p. 664, doi. 10.1111/cts.12928

By:

Goldman, Jonathan W.;
Barve, Minal;
Patel, Jyoti D.;
Wozniak, Antoinette;
Dowlati, Afshin;
Starodub, Alexander;
Owonikoko, Taofeek K.;
Edenfield, William;
Laurie, Scott A.;
Da Costa, Daniel;
Lally, Satwant;
Koch, Martina;
Kosloski, Matthew P.;
Hoffman, David;
Dy, Grace K.

Publication type:

Article

Non-small cell lung cancer clinical trials requiring biopsies with biomarker-specific results for enrollment provide unique challenges.

Published in:

2017

By:

Spiegel, Marshall L.;
Goldman, Jonathan W.;
Wolf, Brian R.;
Nameth, Danielle J.;
Grogan, Tristan R.;
Lisberg, Aaron E.;
Wong, Deborah J. L.;
Ledezma, Blanca A.;
Mendenhall, Melody A.;
Genshaft, Scott J.;
Gutierrez, Antonio J.;
Abtin, Fereidoun;
Wallace, W.Dean;
Adame, Carlos R.;
McKenzie, Jordan R.;
Abarca, Phillip A.;
Li, Alice J.;
Strunck, Jennifer L.;
Famenini, Sina;
Carroll, James M.

Publication type:

journal article

Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.

Published in:

Cancer (0008543X), 2012, v. 118, n. 23, p. 5903, doi. 10.1002/cncr.27575

By:

Goldman, Jonathan W.;
Laux, Isett;
Chai, Feng;
Savage, Ronald E.;
Ferrari, Dora;
Garmey, Edward G.;
Just, Richard G.;
Rosen, Lee S.

Publication type:

Article

Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer.

Published in:

2016

By:

Bendell, Johanna;
Rosen, Lee;
Mayer, Robert;
Goldman, Jonathan;
Infante, Jeffrey;
Benedetti, Fabio;
Lin, Donghu;
Mizuguchi, Hirokazu;
Zergebel, Christopher;
Patel, Manish;
Bendell, Johanna C;
Rosen, Lee S;
Mayer, Robert J;
Goldman, Jonathan W;
Infante, Jeffrey R;
Patel, Manish R

Publication type:

corrected article

Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer.

Published in:

2015

By:

Bendell, Johanna;
Rosen, Lee;
Mayer, Robert;
Goldman, Jonathan;
Infante, Jeffrey;
Benedetti, Fabio;
Lin, Donghu;
Mizuguchi, Hirokazu;
Zergebel, Christopher;
Patel, Manish;
Bendell, Johanna C;
Rosen, Lee S;
Mayer, Robert J;
Goldman, Jonathan W;
Infante, Jeffrey R;
Patel, Manish R

Publication type:

journal article

A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies.

Published in:

BMC Cancer, 2013, v. 13, n. 1, p. 1, doi. 10.1186/1471-2407-13-152

By:

Goldman, Jonathan W.;
Raju, Robert N.;
Gordon, Gregory A.;
El-Hariry, Iman;
Teofilivici, Florentina;
Vukovic, Vojo M.;
Bradley, Robert;
Karol, Michael D.;
Yu Chen;
Wei Guo;
Inoue, Takayo;
Rosen, Lee S

Publication type:

Article

A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies.

Published in:

2013

By:

Goldman, Jonathan W;
Raju, Robert N;
Gordon, Gregory A;
El-Hariry, Iman;
Teofilivici, Florentina;
Vukovic, Vojo M;
Bradley, Robert;
Karol, Michael D;
Chen, Yu;
Guo, Wei;
Inoue, Takayo;
Rosen, Lee S

Publication type:

journal article

Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab -Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer.

Published in:

Frontiers in Oncology, 2019, v. 9, p. 1, doi. 10.3389/fonc.2019.01256

By:

Goldman, Jonathan W.;
Waterhouse, David M.;
George, Ben;
O'Dwyer, Peter J.;
Bhore, Rafia;
Banerjee, Sibabrata;
Lyons, Larry;
Louis, Chrystal U.;
Ong, Teng Jin;
Kelly, Karen

Publication type:

Article

Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.

Published in:

Nature Communications, 2016, v. 7, n. 11, p. 13513, doi. 10.1038/ncomms13513

By:

Chabon, Jacob J.;
Simmons, Andrew D.;
Lovejoy, Alexander F.;
Esfahani, Mohammad S.;
Newman, Aaron M.;
Haringsma, Henry J.;
Kurtz, David M.;
Stehr, Henning;
Scherer, Florian;
Karlovich, Chris A.;
Harding, Thomas C.;
Durkin, Kathleen A.;
Otterson, Gregory A.;
Thomas Purcell, W.;
Ross Camidge, D.;
Goldman, Jonathan W.;
Sequist, Lecia V.;
Piotrowska, Zofia;
Wakelee, Heather A.;
Neal, Joel W.

Publication type:

Article

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.

Published in:

Nature Communications, 2016, v. 7, n. 6, p. 11815, doi. 10.1038/ncomms11815

By:

Chabon, Jacob J.;
Simmons, Andrew D.;
Lovejoy, Alexander F.;
Esfahani, Mohammad S.;
Newman, Aaron M.;
Haringsma, Henry J.;
Kurtz, David M.;
Stehr, Henning;
Scherer, Florian;
Karlovich, Chris A.;
Harding, Thomas C.;
Durkin, Kathleen A.;
Otterson, Gregory A.;
Purcell, W. Thomas;
Camidge, D. Ross;
Goldman, Jonathan W.;
Sequist, Lecia V.;
Piotrowska, Zofia;
Wakelee, Heather A.;
Neal, Joel W.

Publication type:

Article

The evolution of cyclin dependent kinase inhibitors in the treatment of cancer.

Published in:

2021

By:

Jhaveri, Komal;
Burris 3rd, Howard A;
Yap, Timothy A;
Hamilton, Erika;
Rugo, Hope S;
Goldman, Jonathan W;
Dann, Stephen;
Liu, Feng;
Wong, Gilbert Y;
Krupka, Heike;
Shapiro, Geoffrey I

Publication type:

Literature Review

A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER.

Published in:

Frontiers in Oncology, 2020, v. 11, p. N.PAG, doi. 10.3389/fonc.2020.578756

By:

Goldman, Jonathan W.;
Mazieres, Julien;
Barlesi, Fabrice;
Dragnev, Konstantin H.;
Koczywas, Marianna;
Göskel, Tuncay;
Cortot, Alexis B.;
Girard, Nicolas;
Wesseler, Claas;
Bischoff, Helge;
Nadal, Ernest;
Park, Keunchil;
Lu, Shun;
Taus, Alvaro;
Cobo, Manuel;
Estrem, Shawn T.;
Wijayawardana, Sameera R.;
Turner, Kellie;
Oakley III, Gerard Joseph;
Hurt, Karla C.

Publication type:

Article

Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management.

Published in:

Oncologist, 2016, v. 21, n. 11, p. 1326, doi. 10.1634/theoncologist.2015-0519

By:

Goldman, Jonathan W.;
Mendenhall, Melody A.;
Rettinger, Sarah R.

Publication type:

Article

A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia.

Published in:

Journal of Hematology & Oncology, 2017, v. 10, p. 1, doi. 10.1186/s13045-017-0427-x

By:

Vadhan-Raj, Saroj;
Abonour, Rafat;
Goldman, Jonathan W.;
Smith, David A.;
Slapak, Christopher A.;
Ilaria Jr., Robert L.;
Tiu, Ramon V.;
Xuejing Wang;
Callies, Sophie;
Joanne Cox;
Tuttle, Jay L.;
Yiu-Keung Lau;
Roeland, Eric J.

Publication type:

Article

Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer.

Published in:

Investigational New Drugs, 2018, v. 36, n. 4, p. 629, doi. 10.1007/s10637-017-0532-2

By:

Goldman, Jonathan W.;
Rosen, Lee S.;
Tolcher, Anthony W.;
Papadopoulos, Kyriakos;
Beeram, Muralidhar;
Shi, Peipei;
Pitou, Celine;
Bell, Robert;
Kulanthaivel, Palaniappan;
Zhang, Xuekui;
Fink, Aaron;
Chan, Edward M.;
Shahir, Ashwin;
Farrington, Daphne;
Patnaik, Amita

Publication type:

Article

nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC.

Published in:

Frontiers in Oncology, 2018, p. N.PAG, doi. 10.3389/fonc.2018.00262

By:

Langer, Corey J.;
Kim, Edward S.;
Anderson, Eric C.;
Jotte, Robert M.;
Modiano, Manuel;
Haggstrom, Daniel E.;
Socoteanu, Matei P.;
Smith, David A.;
Dakhil, Christopher;
Konduri, Kartik;
Berry, Tymara;
Ong, Teng J.;
Sanford, Alexandra;
Amiri, Katayoun;
Goldman, Jonathan W.;
Weiss, Jared;
on behalf of the ABOUND.70+ Investigators;
Gajra;
Dobrescu;
Halibey

Publication type:

Article

Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.

Published in:

2024

By:

Tsuboi, Masahiro;
Herbst, Roy S.;
John, Thomas;
Kato, Terufumi;
Majem, Margarita;
Grohé, Christian;
Wang, Jie;
Goldman, Jonathan W.;
Lu, Shun;
de Marinis, Filippo;
Shepherd, Frances A.;
Lee, Ki Hyeong;
Le, Nhieu Thi;
Dechaphunkul, Arunee;
Kowalski, Dariusz;
Bonanno, Laura;
Dómine, Manuel;
Poole, Lynne;
Bolanos, Ana;
Rukazenkov, Yuri

Publication type:

Letter

PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin - case report.

Published in:

2018

By:

Goldman, Jonathan W.;
Abdalla, Basmah;
Mendenhall, Melody A.;
Sisk, Anthony;
Hunt, Jaime;
Danovitch, Gabriel M.;
Lum, Erik L.

Publication type:

journal article